← Human Trials & Peer-Reviewed Studies
Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial
Plain-language guide to PMID 15583955 (2005): double-blind randomized controlled trial study of Cerebrolysin.
Key Facts
- PMID
- 15583955
- Journal
- Journal of neural transmission (Vienna, Austria : 1996)
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Ladurner G et al. (3 authors)
- DOI
- 10.1007/s00702-004-0248-2
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Cerebrolysin, published as a randomized controlled trial.
Cerebrolysin is a compound with neurotrophic and neuroprotective activity.
It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids.
The researchers explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Cerebrolysin and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Cerebrolysin, so expectations could not easily colour the readings.
Some participants received a placebo instead of Cerebrolysin, giving a reference point.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Randomised, placebo-controlled, parallel group trial.
Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline.
What Was Measured
The subject headings attached to it are Amino Acids, Neuroprotective Agents and Stroke.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cerebrolysin.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Journal of neural transmission (Vienna, Austria : 1996)), a journal based in Austria.
More context: the Cerebrolysin compound page, all human trials.
Our Notes on the Compound
Cerebrolysin: A mixed neurotrophic preparation (NGF-, BDNF-, GDNF- and CNTF-like activity).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.